share_log

TransCode Therapeutics Shares Are Trading Higher After the Company Announced It's Dosed Patients in the First Cohort of Its Phase 1A Dose-escalation Clinical Trial of TTX-MC138.

Benzinga ·  Oct 10 22:20
TransCode Therapeutics Shares Are Trading Higher After the Company Announced It's Dosed Patients in the First Cohort of Its Phase 1A Dose-escalation Clinical Trial of TTX-MC138.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment